Threshold Pharmaceuticals Inc. (THLD)
-NasdaqCM 5.50 0.00(0.00%) 4:00PM EDT
| Prev Close: | 5.50 |
|---|
| Open: | 5.53 |
|---|
| Bid: | 5.14 x 200 |
|---|
| Ask: | 5.80 x 500 |
|---|
| 1y Target Est: | 13.25 |
|---|
| Beta: | 3.57 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 5.46 - 5.58 |
|---|
| 52wk Range: | 3.95 - 9.28 |
|---|
| Volume: | 304,515 |
|---|
| Avg Vol (3m): | 551,253 |
|---|
| Market Cap: | 311.01M |
|---|
| P/E (ttm): | 8.72 |
|---|
| EPS (ttm): | 0.63 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Threshold Pharmaceuticals: A Biotech That Investors Need To Know Aboutat Motley Fool(Fri, Jun 14)
- Celgene Soars in 2013; What Does the Future Hold?at Motley Fool(Thu, Jun 6)
- THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jun 3)
- Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual MeetingMarketwired(Sun, Jun 2)
- New Pancreatic Cancer Drug an FDA Priorityat Motley Fool(Sun, May 26)
- Tackling Cancer: Pancreatic Cancer's Biggest Current & Upcoming Playersat Motley Fool(Sat, May 25)
- Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 16%at TheStreet(Fri, May 24)
- Investing In Cancer Research Is Worth The Risk: Echo Heat Seeking Alpha(Fri, May 24)
- 3 Market Caps With Exceptionally High ROICat Seeking Alpha(Wed, May 22)
- THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, May 20)
- THRESHOLD PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 10)
- Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor ConferencesMarketwired(Thu, May 9)
- Are These The Biotech Stars Of Tomorrow?StreetAuthority Network(Thu, May 2)
- Threshold Pharmaceuticals Reports First Quarter 2013 Financial and Operational ResultsMarketwired(Thu, May 2)
- THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 36.43 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.58 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Threshold Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of drugs targeting the severe hypoxia in the microenvironment of solid tumors and the bone marrows of patients with hematological malignancies.
View More